New combination improves outcomes for small cell bladder and neuroendocrine prostate cancer patients: early stage but clinical study
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2: Food as Medicine Research from City Of Hope
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/0 Comments/in Observational, Post-hoc, Retrospective studies/by MaxAn add-on strategy to maximize workouts: electro stimulation works for cancer patients
/0 Comments/in Clinical Trial, Metastatic/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/1 Comment/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/0 Comments/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/0 Comments/in Artificial Intelligence/by MaxTags
abiraterone acetate ADC ADT androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody cancer cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology PARP inhibitor PEACE-1 personalized medicine prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery theranostics tumor microenvironment
Latest Posts
- Newsletter 3/2025 January 19, 2025
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025